Lung & Respiratory Disease Clinical Trials Update: Week 16, 2026

Published April 17, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert

A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease

This Phase 3 trial is exploring nerandomilast, an oral medication, to see if it is safe and effective in treating children and adolescents aged 2 to 17 years with fibrosing interstitial lung disease. This is a serious condition where lung tissue becomes scarred, making breathing difficult. The study’s long treatment period of up to five years reflects the importance of understanding how this medicine can support lung health over time in young patients worldwide.

A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy

This Phase 3 study is testing XW003 injections as a treatment for obese adults who have obstructive sleep apnea but are not using the standard positive airway pressure (PAP) devices. Since many patients find PAP therapy difficult or unsuitable, this new approach could offer an alternative way to improve breathing during sleep. The trial is recruiting participants in China, aiming to enroll 140 adults to assess the treatment’s safety and benefits.

A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy

Similar to the previous trial, this study evaluates XW003 injections but focuses on obese adults with obstructive sleep apnea who are already using positive airway pressure therapy. Researchers want to find out if adding XW003 can enhance breathing and sleep quality beyond what PAP devices alone provide. This trial is also recruiting in China and could lead to improved treatment strategies for this common respiratory condition.

A Study to Test How Well BI 3720931 is Tolerated and Whether it Improves Lung Function in People With Cystic Fibrosis (Lenticlair™ 1)

This Phase 1 trial investigates an inhaled gene therapy called BI 3720931 for adults with cystic fibrosis who cannot benefit from current CFTR modulator drugs. Cystic fibrosis causes thick mucus to build up in the lungs, leading to infections and breathing difficulties. If successful, this new gene therapy could offer hope to patients with limited treatment options. The study involved a single dose and careful follow-up across multiple European countries.

CHildhood ASthma and Environment Research Study - CHASER Study

This observational study completed in Italy involved 2,660 children with asthma to better understand what triggers asthma attacks and affects disease control. The research focused on non-drug factors using saliva and urine tests to identify environmental influences. The findings may help improve how asthma is managed in children, leading to fewer attacks and better quality of life.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.